Small bowel intussusception in metastatic endometrial carcinoma. by Kirk, G. R. et al.
The UlsterMedical Journal, Volume 68, No. 2, pp. 110-113, November 1999.
Case Report
Small bowel intussusception in metastatic endometrial
carcinoma
G R Kirk, D O'Rourke, R Ashe, W D B Clements
Accepted 3 November 1999
Endometrial carcinomaisthe secondcommonest
gynaecologicalmalignancy. Survivalisgenerally
betterthanwithothergenitourinarymalignancies
on account of its overt presentation with post-
menopausal bleeding and its tendency for local
progression as opposed to early systemic
dissemination. Consequently, surgery is thegold
standardtherapeutic strategy, andto date there is
little evidence to support the routine use of
adjuvant chemotherapy.' 2
Adult intussusception is very uncommon and
unlike its paediatric counterpart is usually
associated with a significant underlying organic
focus.3 4 When due to secondary malignant
disease,theprimaryneoplasmischaracteristically
aggressive with apropensity for haematogenous
spread. Similarly, splenicmetastases arerareand
characteristically occur in tumours which have a
propensity for blood-borne dissemination.5
Wereport auniquecase ofrecurrentendometrial
carcinoma presenting with small intestinal
intussusception and the incidental finding of a
solitary splenic metastasis. This pattern of
behaviour is very atypical in endometrial
carcinoma. Wediscuss adultintussusception and
present the argument for selective systemic
chemotherapy in endometrial carcinoma.
CASE REPORT A 64-year-old multiparous
woman presented with a three-month history of
episodic post-menopausal bleeding. Cervical
dilatation and endometrial curettage was
performed and histology confirmed the presence
ofapoorlydifferentiatedendometrialcarcinoma.
Atoperation the disease appeared to be confined
to the uterus and cervix. Hysterectomy and
bilateral salpingoophorectomy was performed
with excision of the upper third of the vagina;
lymph nodes were sampled from the internal
iliac,externaliliacandobturatorgroup.Histology
confirmedthepresence ofapoorlydifferentiated
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ileum and the blunted appearance at the site of
the obstruction is typical of an intussusception.
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endometrial carcinoma. There were areas of
microvascular invasion with lymph node
metastases to the internal iliac lymph nodes.
Post-operatively the patient received 50 Gy of
externalbeamradiotherapyandoralprogestogen;
the receptor status of the tumour was unknown.
She remained well and a CT scan performed six
months postoperatively showed no evidence of
macroscopic disease recurrence.
Ten months later she presented with intermittent
crampy abdominal pain and melaena. Clinically
she was anaemic and displayed the physical and
radiological features of small intestinal
obstruction. A small bowel series confirmed the
presence of a mid-ileal obstruction and the
"elephant foot" appearance, suggestive of an
intussusception [Fig 1]. Abdominal ultrasono-
graphy showed no evidence ofascites orhepatic
infiltration; however a 3 cm solitary metastasis
was noted in the upper pole of the spleen. At
laparotomy the small intestine was found to be
distendedproximal to themid-ilealregion where
there was an irreducible intussusception [Fig 2
a+b]. Consequently a limited small-bowel
resection with primary anastomosis was
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Fig 2a & b. These operative specimens show the ileal
intussusception both before and after
reduction. The ulcerated area in picture 2a
clearly shows the endometrial metastases
acting as a lead point for intussusception.
performed, and histopathological assessment
revealedasolitaryfocusofrecurrentendometrial
carcinoma acting as a " lead point".
Thepatientmadeanuncomplicatedrecovery and
was discharged five days later. She remained
well for several months but died from
disseminated disease within nine months.
DISCUSSION
Endometrial carcinoma occurs most commonly
in postmenopausal women in the 6th decade of
life, and the overall five year survival is
approximately 65%.' The majority of tumours
are confined to the uterus and present at an early
stage with postmenopausal bleeding. Most of
these patients have an excellent prognosis when
treated by total abdominal hysterectomy and
bilateral salpingoophorectomy alone, providing
extraperitoneal disease is absent, the carcinoma
iswelldifferentiated andthedepthofmyometrial
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invasion is less than one third.2 Radiotherapy is
used as adjuvant treatment for more advanced
endometrial carcinoma, with areduction in local
recurrencerates. Thelong-term survivalremains
unchanged.8 As in this case, hormonal
manipulation withprogestogens can be used as a
first line adjuvant therapy. The basis for this is
thepresence oftissue-receptor sites in as high as
70% oftumours. Their routine use is ofdoubtful
value. A large randomised placebo controlled
trial of 1084 patients showed no survival
advantage or progression-free period in patients
receiving adjuvant progestogen therapy.9 In
carefully selected patients however, they may be
ofsomevalue. Neijt 10reviewedcurrentliterature
on the systemic treatment of endometrial
carcinomaandsuggestedthatfirst-linetreatment
forthosepatientswhoarereceptorpositiveshould
be hormonal therapy, providing their life
expectancy was greater than four months. If the
receptor status is unknown, but the tumour well
differentiated, then again first-line treatment
should be hormonal therapy. The response rate
however is only about 10-15% and is usually
short lived."1 With gynaecological malignancy
small bowel obstruction occurs commonly. This
is due to direct spread oftumour to small bowel
lying within the pelvis. Endometrial carcinoma
has not previously been described in association
withadultintussusceptionorwithsolitarysplenic
metastases.
Adult intussusception is difficult to diagnose
preoperatively although the triad of melaena,
intestinal obstruction and the presence of an
abdominal mass has been described.12 Barium
studies, ultrasonography and computed
tomography have allbeenemployedwithlimited
success.' 13, 14
Adjuvant chemotherapy aims to ablate
microscopicbloodbornetumourdeposits andhas
beensuccessfullyemployed inbreastcarcinoma,
and more recently in colorectal carcinoma.15' 16
Theuseofchemotherapeutic agentsis associated
with well-recognised morbidity and their global
administration in the treatment ofcancermay be
inappropriate in many patients. It would be ideal
if we could identify those patients who would
benefit most from adjuvant chemotherapy. To
this end some investigators have used specific
clinical andhistological criteriato selectpatients
who may benefit from adjuvant chemotherapy.
Lymph node metastases, initial tumour burden,
and microscopic parameters of the primary
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specimen, suchasthepresenceoflymphovascular
invasion, a high mitotic index and a poor host
immuneresponsemayallhavepositivepredictive
potential for those individuals who may
benefit.9' 10, 15, 19
Todate, cytotoxic therapyhasnotbeenofbenefit
in the management of endometrial carcinoma
with extrauterine spread. Burke et all8 treated 62
high-risk patients who had stage II and stage III
disease . They were given a combination regime
ofcisplatin, doxorubicinandcyclophosphamide.
As expected those with extrauterine disease had
a poorer outcome; their results were found to be
disappointing and at three years one third of
patients had recurrent disease, with a high
proportionofcasesbeingextrapelvic metastases.
Evidence however is now accruing that a role
may exist for adjuvant cytotoxic therapy in the
treatment of uterine carcinoma which is either
confinedtotheuterusorresectablebuthascertain
histological criteria.19 Smith et al in their
retrospectivereview, showedasurvivaladvantage
when they looked at 39 high risk patients given
combinationchemotherapyandradiotherapy. The
two-year progression free interval was 72% in
those patients with non papillary serous
carcinoma, and 22.5% in those with papillary
serous tumours. Their data however was limited
by small numbers and short follow up, but it did
further emphasize the need for prospective
randomised trials to evaluate this form of
treatment.Ourcaseisofparticularinterestbecause
of its unusual presentation. It emphasizes that
local therapies forsuch disease areunlikely tobe
effective without adjuvant systemic therapy to
treat and or prevent haematogenous
dissemination. Unfortunately the correct timing
of this therapy and the patient population likely
to benefit are not yet known.
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